Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT01645735 Completed - Infections Clinical Trials

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Start date: October 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant Staphylococcus aureus (MRSA).

NCT ID: NCT01644643 Completed - Clinical trials for Complicated Urinary Tract Infection

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Start date: January 2013
Phase: Phase 3
Study type: Interventional

To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.

NCT ID: NCT01641809 Completed - HIV Infections Clinical Trials

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Start date: August 6, 2012
Phase: Phase 2
Study type: Interventional

The study is designed to select a dose of GSK1265744 primarily on the basis of antiviral activity and tolerability in HIV-1 infected, antiretroviral naive subjects. This study consists of two parts: Induction Phase: Approximately 200 subjects will be randomized (50 subjects in each of the 4 treatment arms). The Induction Phase consists of a 24 week dose-ranging evaluation of GSK1265744 at blinded doses of 10 mg, 30 mg and 60 mg once-daily and a control arm of open-label efavirenz (EFV) 600 mg once daily. The background dual nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral therapy (ART) for all arms will be either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) as selected by the Investigator. Subjects randomized to a GSK1265744 containing arm, who successfully complete 24 weeks on study and demonstrate virologic suppression (defined as having a plasma HIV-1 ribonucleic acid [RNA] <50 copies per milliliter [c/mL] before Week 24, with no signs of virologic rebound) will become eligible for the Maintenance Phase of this study. Maintenance Phase: The background NRTIs will be discontinued and the subjects will continue their randomized dose of GSK1265744 in combination with rilpivirine (RPV) 25 mg once-daily for an additional 72 weeks. The Maintenance phase will evaluate the ability of this two drug ART regimen to maintain virologic suppression through Week 48, Week 72 and Week 96. Subjects randomized to the EFV arm will continue on their randomized regimen through Week 96. After completion of the maintenance phase, subjects could enroll in the Open-Label Phase to continue GSK1265744 + RPV treatment as long as they continue to derive clinical benefit and until it is locally approved and commercially available.

NCT ID: NCT01640925 Completed - Clinical trials for Surgical Wound Infection

Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit

Start date: July 2012
Phase: N/A
Study type: Interventional

This prospective, randomized, controlled trial will compare the incidence of nosocomial infections (composite of primary bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and surgical site infections) that occur in intensive care unit (ICU) patients bathed with 2% chlorhexidine solution versus patients who receive standard bathing (soap and water or non-medicated cloths).

NCT ID: NCT01639430 Completed - Infection Clinical Trials

Diagnostic Accuracy of Body Temperature Measurement in Geriatric Patients

Start date: May 2012
Phase: N/A
Study type: Observational

Retrospective analysis of a quality measurement project examining the quality of vital parameter measurement in consecutive patients >= 75 years presenting to the emergency department. Primary goal of the study is to evaluate the diagnostic accuracy of body temperature measurement using different methods to diagnose infection in patients >= 75 years presenting to the emergency department. The secondary goal is to compare the reliability of tympanal and temporal artery thermometry with rectal temperature measurement.

NCT ID: NCT01637870 Completed - Wound Infection Clinical Trials

Negative Pressure Wound Therapy After Cesarean Delivery

Start date: August 2012
Phase: N/A
Study type: Interventional

This study is aimed at determining whether or not the use of a wound suction device placed on the cesarean incision instead of a standard sterile dressing will decrease the prevalence of wound complications and wound infections in women at high risk for post operative complications. The study will first look at the infection and wound complication rate in women 6 months prior to the start date of the study by reviewing charts of women who have undergone a cesarean section. The study involves placing a single use, portable wound vacuum over the cesarean section incision and keeping it in place for 72h. The investigators will then compare the rates of wound infection and wound complications between these two groups. It is our hypothesis that negative pressure wound systems will decrease the wound infection and complication rate in this high risk population.

NCT ID: NCT01634477 Completed - Healthy Clinical Trials

Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study

TNT-HIV
Start date: January 2010
Phase:
Study type: Observational

1. To describe the morbidity and clinical characteristics among HIV-infected patients and HIV-uninfected patients. 2. To identify the risk factors for the complication or morbidity among HIV-infected patients and HIV-uninfected patients. 3. To describe the mortality among HIV-infected patients and HIV-uninfected patients. 4. To identify the risk factors for the cause of death among HIV-infected and HIV-uninfected patients.

NCT ID: NCT01631968 Completed - Clinical trials for Infection After Primary Total Knee Arthroplasty

Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement

Start date: September 2007
Phase: N/A
Study type: Interventional

Prospective randomized study in cemented primary total knee arthroplasty. In one group the cement used was standard cement, without any antibiotics and in the other group the cement used was loaded with 0.5 g of erythromycin and 3 million units of colistin in 40 g of cement. In all cases intravenous antibiotics prophylaxis against infection was used. In both groups the cement was mechanically mixed in a vacuum. One deep drain tube was placed for 24 hours in all cases. The main variable was the presence of infection according to the Center of Disease Control criteria with a minimum of 12 months follow-up.

NCT ID: NCT01631461 Completed - Breast Infection Clinical Trials

Painful Breastfeeding and Bacterial or Yeast Infection

Start date: December 2006
Phase: N/A
Study type: Observational

The aim of this study is to investigate the prevalence of yeast and bacteria in women with breastfeeding pain and to identify signs and symptoms.

NCT ID: NCT01631201 Completed - Clinical trials for Chlamydia Trachomatis Infection

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

Start date: July 2012
Phase: Phase 2
Study type: Interventional

This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a single dose to women who have genital chlamydial infection.